Previous Close | 14.74 |
Open | 14.74 |
Bid | 14.67 x 2200 |
Ask | 14.70 x 2200 |
Day's Range | 14.68 - 14.75 |
52 Week Range | 11.45 - 15.89 |
Volume | |
Avg. Volume | 101,718 |
Market Cap | 213.678M |
Beta (5Y Monthly) | 1.41 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.08 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Dec 13, 2019 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for MACK
CAMBRIDGE, Mass., March 07, 2024--Merrimack Reports Full Year 2023 Financial Results
Key Insights Significantly high institutional ownership implies Merrimack Pharmaceuticals' stock price is sensitive to...
CAMBRIDGE, Mass., February 13, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") reported that Ipsen, SA ("Ipsen") issued a press release today announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma (mPDAC).